JP2023537840A5 - - Google Patents

Info

Publication number
JP2023537840A5
JP2023537840A5 JP2023501570A JP2023501570A JP2023537840A5 JP 2023537840 A5 JP2023537840 A5 JP 2023537840A5 JP 2023501570 A JP2023501570 A JP 2023501570A JP 2023501570 A JP2023501570 A JP 2023501570A JP 2023537840 A5 JP2023537840 A5 JP 2023537840A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
transdermal
composition according
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023501570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537840A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/057483 external-priority patent/WO2022038479A1/en
Publication of JP2023537840A publication Critical patent/JP2023537840A/ja
Publication of JP2023537840A5 publication Critical patent/JP2023537840A5/ja
Pending legal-status Critical Current

Links

JP2023501570A 2020-08-17 2021-08-13 ナビロンを単独及びカンナビノイドと併用する経皮製剤 Pending JP2023537840A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063066386P 2020-08-17 2020-08-17
US63/066,386 2020-08-17
US202163229021P 2021-08-03 2021-08-03
US63/229,021 2021-08-03
PCT/IB2021/057483 WO2022038479A1 (en) 2020-08-17 2021-08-13 Transdermal pharmaceutical formulations of cannabinoids

Publications (2)

Publication Number Publication Date
JP2023537840A JP2023537840A (ja) 2023-09-06
JP2023537840A5 true JP2023537840A5 (https=) 2024-08-20

Family

ID=80223734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023501570A Pending JP2023537840A (ja) 2020-08-17 2021-08-13 ナビロンを単独及びカンナビノイドと併用する経皮製剤
JP2023503426A Pending JP2023537675A (ja) 2020-08-17 2021-08-13 パーキンソン病の治療のための医薬組成物及びその治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023503426A Pending JP2023537675A (ja) 2020-08-17 2021-08-13 パーキンソン病の治療のための医薬組成物及びその治療方法

Country Status (8)

Country Link
US (3) US20220047525A1 (https=)
EP (2) EP4196113A4 (https=)
JP (2) JP2023537840A (https=)
CN (2) CN115884760A (https=)
AU (2) AU2021328742A1 (https=)
CA (2) CA3187588A1 (https=)
MX (2) MX2023000314A (https=)
WO (2) WO2022038479A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP4046630A1 (en) * 2021-02-18 2022-08-24 LTS Lohmann Therapie-Systeme AG Tts-formulation with thc
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN117545478A (zh) * 2021-04-22 2024-02-09 长矛治疗股份有限公司 用于治疗慢性疼痛的透皮药物制剂
WO2023012691A1 (en) * 2021-08-03 2023-02-09 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
GB202206000D0 (en) * 2022-04-25 2022-06-08 Univ Stellenbosch Leonotis leonurus extracts as a chemoprotectant and post-chemotherapeutic agent
EP4558135A1 (en) * 2022-07-21 2025-05-28 Pike Therapeutics Inc. Continuous delivery systems comprising a cannabinoid and medicinal uses thereof
CN116077419B (zh) * 2023-02-24 2023-10-27 丽珠集团新北江制药股份有限公司 一种犬用盐酸司来吉兰透皮吸收剂及其制备方法
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation
CN116617161B (zh) * 2023-07-26 2023-10-24 中国科学院理化技术研究所 一种包含大麻二酚混悬液的可溶性微针及其制备方法
WO2026018119A1 (en) * 2024-07-16 2026-01-22 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US6617356B2 (en) * 2000-01-03 2003-09-09 Naturally Scientific Inc Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20020111377A1 (en) * 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
US20100184848A1 (en) * 2006-07-14 2010-07-22 William Abraham Wine Transdermal formulations of synthetic cannabinoids and nano colloidal silica
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
EP2476414B1 (en) * 2009-09-07 2015-03-04 NIPRO Patch Co., Ltd. Transdermally absorbable preparation
AU2011281336B2 (en) * 2010-07-20 2015-03-05 Junaxo, Inc. Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders
CA2882870C (en) * 2012-08-24 2020-12-15 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
US10098895B2 (en) * 2016-09-07 2018-10-16 Glia, Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
CN109963595B (zh) * 2016-10-11 2023-02-03 Gbs全球生物制药公司 用于治疗神经退行性疾病的含有大麻素的复合混合物
US20180360757A1 (en) * 2017-05-26 2018-12-20 Altum Pharmaceuticals Inc. Biphasix cannabinoid delivery
CN111093639A (zh) * 2017-09-05 2020-05-01 罗曼治疗系统股份公司 用于卡巴拉汀经皮给药的经皮治疗系统
US20190083388A1 (en) * 2017-09-19 2019-03-21 Zynerba Pharmaceuticals, Inc. Synthentic transdermal cannabidiol for the treatment of focal epilepsy in adults
US11141172B2 (en) * 2018-04-11 2021-10-12 Globus Medical, Inc. Method and apparatus for locking a drill guide in a polyaxial hole
CN112996491A (zh) * 2018-10-15 2021-06-18 阿姆农·瓦尔迪 缓释大麻素及其产品
US11660283B2 (en) * 2018-12-19 2023-05-30 Joyn Botanicals Ltd. Cannabinoid-containing composition
EP3902553A4 (en) * 2018-12-27 2022-10-05 Buzzelet Development And Technologies Ltd HERB-INFUSED CANNABINOID COMPOSITION AND METHODS OF TREATMENT
EP3906025A4 (en) * 2019-01-04 2022-09-21 Columbia Care LLC CANNABINOID TOPICAL FORMULATIONS
US11026896B2 (en) * 2019-06-18 2021-06-08 Dyve Biosciences, Inc. Transdermal penetrant formulations containing cannabidiol
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis

Similar Documents

Publication Publication Date Title
JP2023537840A5 (https=)
JP2022551696A5 (https=)
JP2022551730A5 (https=)
US8030314B2 (en) Use of 2h-benzimidazol-2-one, 1,3-dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable acid addition salts
US10383816B2 (en) Topical regional neuro-affective therapy with cannabinoid combination products
CN115884761A (zh) 大麻素的透皮药物制剂
CA2386297A1 (en) Bicyclic amino acids as pharmaceutical agents
US10583098B2 (en) Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds
HUE034235T2 (en) Use of cannabidiol prodrugs in topical and transdermal delivery with microdisks
EA201500553A1 (ru) Многодневный пластырь для чрескожного введения ротиготина
JP2022549335A5 (https=)
JP2008535873A5 (https=)
CN105327349A (zh) Nmda受体拮抗剂的医药用途及其药物组合物
CA2704921C (en) Compositions and methods for treating parkinson's disease and related disorders
CN117479930A (zh) 用于治疗癫痫发作病症的药物组合物和方法
JP2024514362A (ja) 慢性疼痛の処置のための経皮医薬製剤
US20150105349A1 (en) (R)-(-)-1,2-propanediol compositions and methods
US7629378B2 (en) Compositions and method for treating affective, painful or allergic disorders
JP2016510332A (ja) 治療配合物（ｃｏｍｐｏｕｎｄｓ）
WO2019030772A1 (en) OIL-BASED FORMULATION FOR THE TREATMENT OF HEALING / PAIN
CN1651397A (zh) 一种含有脂肪酸的薄荷醇衍生物及含有该衍生物的制剂
ATE453392T1 (de) Imidazolcarbonsäurealkylester-haltiges medikament zur behandlung neurodegenerativer erkrankungen
ES2739658T3 (es) Composición de hidrogel para el tratamiento de trastornos dermatológicos
CA2869243C (en) Composition for the treatment of inflammatory and immune disorders
US20230405077A1 (en) Composition for treating pain and method of use thereof